← Leaderboards
Davangere P Devanand
Columbia University Health Sciences
$43,591,695
Attributed
$46,194,073
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$46,194,073 · 13
By mechanism
R01$44,961,637 · 11
R56$821,822 · 1
P01$410,614 · 1
Top collaborators
- Jose A Luchsinger7 shared
- Ashwini K. Rao1 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Stavros Lomvardas$27,353,627
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposDementiaS DiseaseImpaired CognitionCognitiveMagnetic Resonance ImagingMild Cognitive ImpairmentBaseOdorsCognitionApolipoprotein EElderlyUniversitiesBiological MarkersClinical TrialsBrainPharmaceutical PreparationsHippocampus (Brain)RandomizedFutureResponseCognitive TestingPlacebosImpairment
Grant awards (68)
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT$1,670,656
R01 · FY2025 · AG · contact PI
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT$1,813,346
R01 · FY2024 · AG · contact PI
OLFACTORY IMPAIRMENT IN OFFSPRING STUDY OF RACIAL DISPARITIES IN ALZHEIMER'S DISEASE$353,236
R01 · FY2022 · AG · contact PI
Anti-Viral therapy in Alzheimer's disease$2,335,690
R01 · FY2021 · AG · contact PI
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT$880,337
R01 · FY2021 · AG · contact PI
Testing Olfaction in Primary care to detect Alzheimer's disease and other Dementias (TOPAD)$750,182
R01 · FY2021 · AG
OLFACTORY IMPAIRMENT IN OFFSPRING STUDY OF RACIAL DISPARITIES IN ALZHEIMER'S DISEASE$353,236
R01 · FY2021 · AG · contact PI
Anti-Viral therapy in Alzheimer's disease$2,372,211
R01 · FY2020 · AG · contact PI
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT$891,038
R01 · FY2020 · AG · contact PI
Testing Olfaction in Primary care to detect Alzheimer's disease and other Dementias (TOPAD)$875,377
R01 · FY2020 · AG
OLFACTORY IMPAIRMENT IN OFFSPRING STUDY OF RACIAL DISPARITIES IN ALZHEIMER'S DISEASE$353,236
R01 · FY2020 · AG · contact PI
Testing Olfaction in Primary care to detect Alzheimer's disease and other Dementias (TOPAD)$112,023
R01 · FY2020 · AG
COGNITIVE TRAINING AND NEUROPLASTICY IN MILD COGNITIVE IMPAIRMENT$31,587
R01 · FY2020 · AG · contact PI
Anti-Viral therapy in Alzheimer's disease$2,372,211
R01 · FY2019 · AG · contact PI
Auditory, olfactory, and motor correlates of in-vivo AD neuropathology and cognitive decline in late-middle age$821,822
R56 · FY2019 · AG
Testing Olfaction in Primary care to detect Alzheimer's disease and other Dementias (TOPAD)$774,053
R01 · FY2019 · AG
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT$739,075
R01 · FY2019 · AG · contact PI
OLFACTORY IMPAIRMENT IN OFFSPRING STUDY OF RACIAL DISPARITIES IN ALZHEIMER'S DISEASE$353,236
R01 · FY2019 · AG · contact PI
Anti-viral Therapy in Alzheimer's Disease$200,549
R01 · FY2019 · AG · contact PI
Anti-Viral therapy in Alzheimer's disease$1,312,757
R01 · FY2018 · AG · contact PI
Testing Olfaction in Primary care to detect Alzheimer's disease and other Dementias (TOPAD)$785,438
R01 · FY2018 · AG
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT$749,559
R01 · FY2018 · AG · contact PI
Anti-viral therapy in Alzheimer's disease$726,389
R01 · FY2018 · AG · contact PI
Treatment of psychosis and agitation in Alzheimers disease$576,550
R01 · FY2018 · AG · contact PI
OLFACTORY IMPAIRMENT IN OFFSPRING STUDY OF RACIAL DISPARITIES IN ALZHEIMER'S DISEASE$353,236
R01 · FY2018 · AG · contact PI
Anti-Viral therapy in Alzheimer's disease$1,327,757
R01 · FY2017 · AG · contact PI
Testing Olfaction in Primary care to detect Alzheimer's disease and other Dementias (TOPAD)$811,920
R01 · FY2017 · AG
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT$781,608
R01 · FY2017 · AG · contact PI
Olfactory deficits and donepezil treatment in cognitively impaired elderly$599,526
R01 · FY2017 · AG · contact PI
Treatment of psychosis and agitation in Alzheimers disease$579,302
R01 · FY2017 · AG · contact PI
Olfactory deficits and donepezil treatment in cognitively impaired elderly$622,946
R01 · FY2016 · AG · contact PI
Treatment of psychosis and agitation in Alzheimers disease$579,302
R01 · FY2016 · AG · contact PI
Olfactory deficits and donepezil treatment in cognitively impaired elderly$159,726
R01 · FY2016 · AG · contact PI
Olfactory deficits and donepezil treatment in cognitively impaired elderly$604,258
R01 · FY2015 · AG · contact PI
Treatment of psychosis and agitation in Alzheimers disease$561,923
R01 · FY2015 · AG · contact PI
Olfactory deficits and donepezil treatment in cognitively impaired elderly$622,946
R01 · FY2014 · AG · contact PI
Treatment of psychosis and agitation in Alzheimers disease$579,302
R01 · FY2014 · AG · contact PI
Olfactory deficits and donepezil treatment in cognitively impaired elderly$622,946
R01 · FY2013 · AG · contact PI
Pilot Combination Treatment Trial of Mild Cognitive Impairment with Depression$585,011
R01 · FY2013 · AG · contact PI
Pilot Combination Treatment Trial of Mild Cognitive Impairment with Depression$101,079
R01 · FY2013 · AG · contact PI
Pilot Combination Treatment Trial of Mild Cognitive Impairment with Depression$630,320
R01 · FY2012 · AG · contact PI
Questionable Dementia: Course and Predictors of Outcome$116,739
R01 · FY2012 · AG · contact PI
Questionable Dementia: Course and Predictors of Outcome$730,587
R01 · FY2011 · AG · contact PI
Pilot Combination Treatment Trial of Mild Cognitive Impairment with Depression$661,553
R01 · FY2011 · AG · contact PI
Questionable Dementia: Course and Predictors of Outcome$851,817
R01 · FY2010 · AG · contact PI
Questionable Dementia: Course and Predictors of Outcome$837,659
R01 · FY2009 · AG · contact PI
Questionable Dementia: Course and Predictors of Outcome$807,386
R01 · FY2008 · AG · contact PI
Antipsychotic Discontinuation in Alzheimer s Disease$100,000
R01 · FY2008 · AG · contact PI
OLFACTORY IDENTIFICATION DEFICITS AS AN EARLY MARKER OF MILD COGNITIVE IMPAIRMENT$84,560
P01 · FY2008 · AG · contact PI
Antipsychotic Discontinuation in Alzheimer s Disease$884,034
R01 · FY2007 · AG · contact PI
Questionable Dementia: Course and Predictors of Outcome$766,975
R01 · FY2007 · AG · contact PI
OLFACTORY IDENTIFICATION DEFICITS AS AN EARLY MARKER OF MILD COGNITIVE IMPAIRMENT$89,143
P01 · FY2007 · AG · contact PI
Antipsychotic Discontinuation in Alzheimer s Disease$895,987
R01 · FY2006 · AG · contact PI
QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME$116,284
R01 · FY2006 · AG · contact PI
OLFACTORY IDENTIFICATION DEFICITS AS AN EARLY MARKER OF MILD COGNITIVE IMPAIRMENT$81,316
P01 · FY2006 · AG · contact PI
Antipsychotic Discontinuation in Alzheimer s Disease$904,527
R01 · FY2005 · AG
NEUROIMAGING CORRELATES OF ECT OUTCOMES$391,019
R01 · FY2005 · MH
OLFACTORY IDENTIFICATION DEFICITS AS AN EARLY MARKER OF MILD COGNITIVE IMPAIRMENT$78,946
P01 · FY2005 · AG
Antipsychotic Discontinuation in Alzheimer s Disease$895,857
R01 · FY2004 · AG
QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME$656,169
R01 · FY2004 · AG
OLFACTORY IDENTIFICATION DEFICITS AS AN EARLY MARKER OF MILD COGNITIVE IMPAIRMENT$76,649
P01 · FY2004 · AG
Antipsychotic Discontinuation in Alzheimer s Disease$892,028
R01 · FY2003 · AG
QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME$639,123
R01 · FY2003 · AG
QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME$622,565
R01 · FY2002 · AG
QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME$606,486
R01 · FY2001 · AG
TREATMENT OF BEHAVIORAL SYMPTOMS IN ALZHEIMERS DISEASE$246,860
R01 · FY2001 · MH
QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME$592,973
R01 · FY2000 · AG
TREATMENT OF BEHAVIORAL SYMPTOMS IN ALZHEIMERS DISEASE$239,929
R01 · FY2000 · MH